Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, December 18, 2018
[ Tue, Dec 18th 2018
] - WOPRAI
[ Tue, Dec 18th 2018
] - WOPRAI
[ Tue, Dec 18th 2018
] - WOPRAI
[ Tue, Dec 18th 2018
] - WOPRAI
[ Tue, Dec 18th 2018
] - WOPRAI
[ Tue, Dec 18th 2018
] - WOPRAI
[ Tue, Dec 18th 2018
] - WOPRAI
[ Tue, Dec 18th 2018
] - WOPRAI
[ Tue, Dec 18th 2018
] - WOPRAI
[ Tue, Dec 18th 2018
] - WOPRAI
[ Tue, Dec 18th 2018
] - WOPRAI
[ Tue, Dec 18th 2018
] - WOPRAI
[ Tue, Dec 18th 2018
] - WOPRAI
Mon, December 17, 2018
[ Mon, Dec 17th 2018
] - WOPRAI
[ Mon, Dec 17th 2018
] - WOPRAI
[ Mon, Dec 17th 2018
] - WOPRAI
[ Mon, Dec 17th 2018
] - WOPRAI
[ Mon, Dec 17th 2018
] - WOPRAI
[ Mon, Dec 17th 2018
] - WOPRAI
[ Mon, Dec 17th 2018
] - WOPRAI
[ Mon, Dec 17th 2018
] - WOPRAI
[ Mon, Dec 17th 2018
] - WOPRAI
[ Mon, Dec 17th 2018
] - WOPRAI
[ Mon, Dec 17th 2018
] - WOPRAI
[ Mon, Dec 17th 2018
] - WOPRAI
[ Mon, Dec 17th 2018
] - WOPRAI
[ Mon, Dec 17th 2018
] - WOPRAI
[ Mon, Dec 17th 2018
] - WOPRAI
[ Mon, Dec 17th 2018
] - WOPRAI
Christopher Marai Maintained (SNDX) at Strong Buy with Decreased Target to $12 on, Dec 17th, 2018
Christopher Marai of Nomura, Maintained "Syndax Pharmaceuticals, Inc." (SNDX) at Strong Buy with Decreased Target from $22 to $12 on, Dec 17th, 2018.
Christopher has made no other calls on SNDX in the last 4 months.
There are 2 other peers that have a rating on SNDX. Out of the 2 peers that are also analyzing SNDX, 1 agrees with Christopher's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- David Lebowitz of "Morgan Stanley" Downgraded from Buy to Hold on, Monday, October 29th, 2018
This is the rating of the analyst that currently disagrees with Christopher
- Joel Beatty of "Citigroup" Maintained at Strong Buy with Decreased Target to $12 on, Thursday, October 11th, 2018
